FAQ

Refractory B-Cell Non-Hodgkin Lymphoma

Known as: B-Cell Lymphoma Refractory, Refractory B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin's Lymphoma 
B-cell non-Hodgkin lymphoma that is resistant to treatment.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2017
0246819912017

Related topics

Related topics

13 relations
Atypical lymphocyteB-LymphocytesHematopoietic and Lymphatic SystemHematopoietic and Lymphoid Cell
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Refractory B-Cell Non-Hodgkin Lymphoma
cancer cell
Neoplastic Cell
Plasma Cells
Lymphoid Tissue
B-Lymphocytes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
As CD20 has become an established target for treating B-cell malignancies, there is interest in developing anti-CD20 antibodies… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Inotuzumab ozogamicin (CMC-544), a humanized anti-CD22 antibody conjugated to the potent cytotoxic antibiotic calicheamicin… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
PURPOSE The growth of non-Hodgkin lymphomas can be influenced by tumor-immune system interactions. Cytotoxic T-lymphocyte antigen… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2009
2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell…
PURPOSE To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2008
2008
Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.
PURPOSE B-lymphocyte stimulator and a proliferation-inducing ligand regulate B-cell homeostasis and immunoglobulin production and… (More)
Is this relevant?
2007
2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
PURPOSE Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma… (More)
Is this relevant?
2004
2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
PURPOSE Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL). We now provide updated and… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3
Is this relevant?